Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States

被引:8
|
作者
Su, Jun [1 ]
Bylsma, Lauren C. [2 ]
Jiang, Xiaohui [2 ]
Morales Arias, Jaime [1 ]
Jain, Nisha [1 ]
Nordyke, Robert J. [3 ]
机构
[1] Sanofi, 50 Binney St, Cambridge, MA 02142 USA
[2] EpidStrategies, Ann Arbor, MI USA
[3] Beta6 Consulting Grp, Los Angeles, CA USA
关键词
Disease burden; healthcare resource utilization; cold agglutinin disease; autoimmune hemolytic anemia; database analysis; BURDEN; ANEMIA; COSTS;
D O I
10.1080/13696998.2020.1764006
中图分类号
F [经济];
学科分类号
02 ;
摘要
Aims: Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia associated with increased thromboembolism risk and early mortality. Healthcare resource utilization (HRU) in CAD has not been reported. We aimed to compare HRU of patients with CAD with a matched non-CAD cohort in the United States. Materials and methods: Patients with CAD were identified from 2006 to 2016 in the Optum-Humedica database using CAD terms in clinical notes and hematologist review. Patients were required to have Integrated Delivery Network records and >= 6 months' follow-up before and after the first CAD mention date (index date). Patients with CAD were matched to a non-CAD cohort based on demographics. Multivariate analyses assessed inpatient hospitalizations, outpatient visits, emergency room visits, and transfusion use between cohorts 6 months before and 12 months after the index date. Results: Of 814 patients with CAD, 410 met inclusion criteria and were matched to 3,390 patients without CAD. Mean age of patients with CAD was 68.0 years; approximately 62% were female. In the 12 months after the index date, mean inpatient hospitalizations (0.83 vs. 0.25), outpatient visits (17.26 vs. 6.77), emergency room visits (0.55 vs. 0.32), and transfusion days (1.05 vs. 0.05) were higher for patients with CAD than the matched non-CAD cohort (all p < .0001). Similarly, in the 6 months before the index date, patients with CAD had higher HRU than matched patients without CAD for all measures evaluated. Limitations: Results of this study are based on patient information from the Optum-Humedica database, which is limited to commercially insured patients and may not represent the overall CAD population. Conclusions: CAD places a substantial burden on patients and healthcare systems. In addition, the high HRU for patients with CAD observed in the 6 months before diagnosis indicates that disease awareness and better diagnostic practices may be needed.
引用
收藏
页码:902 / 907
页数:6
相关论文
共 50 条
  • [32] HEALTHCARE RESOURCE UTILIZATION AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN THE UNITED STATES
    Sarker, J.
    Lien, H.
    Jetanalin, P.
    Kim, K.
    VALUE IN HEALTH, 2023, 26 (06) : S393 - S393
  • [33] Incremental Costs and Healthcare Resource Utilization Associated with Advanced Liver Disease among Commercially-Insured Patients with Chronic Hepatitis C Virus
    Scaife, Jillian G.
    Kuti, Effie
    Kokkotos, Fotios K.
    Miyasato, Gavin S.
    Lim, Joseph K.
    Wang, Zheng
    Anhalt, Daina S.
    Sander, Stephen
    Sanchez, Herman
    HEPATOLOGY, 2013, 58 : 1281A - 1282A
  • [34] Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States
    Goodin, Douglas S.
    Corwin, Michael
    Kaufman, David
    Golub, Howard
    Reshef, Shoshana
    Rametta, Mark J.
    Knappertz, Volker
    Cutter, Gary
    Pleimes, Dirk
    PLOS ONE, 2014, 9 (08):
  • [35] Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States
    Zhou, Zhou
    Fan, Yanni
    Tang, Wenxi
    Liu, Xinyue
    Thomason, Darren
    Zhou, Zheng-Yi
    Macaulay, Dendy
    Fischer, Aryeh
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (08) : 920 - 927
  • [36] The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States
    Rice, J. Bradford
    White, Alan G.
    Galebach, Philip
    Korenblat, Kevin M.
    Wagh, Aneesha
    Lovelace, Belinda
    Wan, George J.
    Jamil, Khurram
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (08) : 1473 - 1480
  • [37] Healthcare Utilization and Costs in Commercially Insured Patients with AL Amyloidosis
    Quock, Tiffany P.
    Yan, Jessie T.
    Chang, Eunice
    Guthrie, Spencer D.
    Broder, Michael S.
    BLOOD, 2017, 130
  • [38] Longitudinal Analysis of Anemia Severity, Treatment and Healthcare Resource Utilization Among Patients with Primary Cold Agglutinin Disease in a Large US Database
    Wilson, Amanda
    Joly, Florence
    Miles, Gandarvaka
    Kuang, Kammy
    Pham, Huy P.
    BLOOD, 2020, 136
  • [39] Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States
    Wu, Ning
    Yu, Yanni F.
    Chuang, Chien-Chia
    Wang, Rosa
    Benjamin, Nicole N.
    Coultas, David B.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (04) : 249 - 257
  • [40] Healthcare resource utilization and cost among patients with type 1 diabetes in the United States
    Simeone, Jason C.
    Shah, Surbhi
    Ganz, Michael L.
    Sullivan, Sean
    Koralova, Anne
    LeGrand, Jackie
    Bushman, Jesse
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (11): : 1399 - 1410